Physician profile
Stephen Bagnoli
NPI 1649270638
$7,233.63
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,352 · 2020: $1,244 · 2021: $1,314 · 2022: $1,511 · 2023: $1,094 · 2024: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,021.74 | 2019-2024 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,193.16 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $581.34 | 2019-2024 | Ofev, Stiolto Respimat |
| Insmed, INC. | $492.95 | 2019-2024 | Arikayce |
| Mylan Specialty L.P. | $482.53 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $382.68 | 2019-2023 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $221.90 | 2020-2024 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $184.28 | 2021-2024 | Glassia |
| Philips North America LLC | $158.40 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $137.89 | 2019-2024 | Dupixent |
| Genzyme Corporation | $133.76 | 2019-2024 | |
| Genentech USA, INC. | $132.82 | 2019 | |
| Mallinckrodt Hospital Products INC. | $124.45 | 2020-2023 | Acthar |
| Shire North American Group INC | $90.23 | 2019 | |
| Amgen INC. | $88.96 | 2022-2024 | Tezspire |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $84.33 | 2019-2020 | |
| Electromed, INC. | $71.24 | 2019-2023 | Smartvest |
| Ani Pharmaceuticals, INC. | $66.23 | 2023 | Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $61.50 | 2020 | |
| Jazz Pharmaceuticals INC. | $61.23 | 2021 | |
| Circassia INC. | $56.00 | 2019 | |
| Vifor Pharma, INC. | $54.31 | 2024 | Zemaira |
| Inogen, INC. | $53.97 | 2021-2022 | |
| Gilead Sciences, INC. | $50.03 | 2019-2021 | |
| Harmony Biosciences LLC | $43.37 | 2022-2024 | |
| Axsome Therapeutics, INC. | $41.97 | 2022-2023 | Sunosi |
| Pulmonx Corporation | $40.08 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Eisai INC. | $27.87 | 2022 | |
| Pfizer INC. | $24.56 | 2023 | |
| Novartis Pharmaceuticals Corporation | $20.98 | 2022 | |
| Mallinckrodt Enterprises LLC | $19.58 | 2019 | |
| Merck Sharp & Dohme LLC | $15.57 | 2019 | |
| Baxter Healthcare | $13.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bagnoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.